Altered urinary excretion of pteridines in neoplastic disease. Determination of biopterin, neopterin, xanthopterin, and pterin.
Urinary pteridine concentrations in healthy control subjects and patients with cancer and non-malignant diseases were determined by HPLC and TLC after partial purification by ion exchange and Sephadex chromatography. Elevated concentrations of neopterin were found in 70% of the 50 cancer patients investigated. In patients with non-Hodgkin's lymphoma (seven cases) or with liver metastases (12 cases) neopterin concentrations were significantly higher than in control subjects (p < 0.01). Biopterin was less frequently increased (22%). Xanthopterin was generally raised when neopterin and/or biopterin excretion was high. Neopterin/biopterin ratios were higher in some patients with cancer or with severe renal insufficiency than in controls. These findings suggest that alterations in pteridine metabolism are common in malignant disease. The pathogenic, diagnostic and therapeutic significance of these changes remains to be established.
D001708:Biopterins / Q000031:analogs & derivatives / Q000652:urine*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D002855:Chromatography, Thin Layer / Q000379:methods; D003404:Creatinine / Q000652:urine; D006801:Humans; D008223:Lymphoma / Q000652:urine; D009369:Neoplasms / Q000652:urine*; D019798:Neopterin; D011621:Pteridines / Q000652:urine*; D011622:Pterins / Q000652:urine*; D014976:Xanthopterin / Q000652:urine*
D011621:Pteridines; D011622:Pterins; D001708:Biopterins; D019798:Neopterin; D003404:Creatinine; D014976:Xanthopterin